Ronald Palm
Family Medicine · Keizer, ORNPI 1326174301
Payments from drug & device makers
Across 154 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$617
- AstraZeneca$279
- Novo Nordisk$270
- Pfizer$232
- Johnson & Johnson$229
- Biohaven Pharmaceutical Holding Company Ltd.$150
- plus $802 from 15 others
What the payments were for
- Food & beverage$2,55899%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $617 |
| AstraZeneca | 18 | $279 |
| Novo Nordisk | 16 | $270 |
| Pfizer | 11 | $232 |
| Johnson & Johnson | 13 | $229 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $150 |
| Otsuka America Pharmaceutical, Inc. | 8 | $148 |
| GSK | 8 | $126 |
| Bayer | 7 | $108 |
| Medicure Pharma Inc. | 2 | $74 |
| Biohaven Pharmaceuticals, Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Lundbeck LLC | 3 | $52 |
| Impulse Dynamics (USA) Inc. | 3 | $40 |
| Lilly USA, LLC | 2 | $34 |
| Hologic Sales And Service, LLC | 2 | $25 |
| Boehringer Ingelheim | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$2,579 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $72,717 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $38,711 |
| FarxigaDapagliflozin Propanediol | 21 | $26,628 |
| XareltoRivaroxaban | 32 | $25,976 |
| EliquisApixaban | 17 | $24,576 |
| TrulicityDulaglutide | 15 | $21,996 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 11 | $13,830 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,011 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $7,607 |
| VascepaIcosapent Ethyl | 12 | $4,544 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $3,512 |
| Gabapentin | 109 | $3,390 |
| Celecoxib | 18 | $3,370 |
| Omeprazole | 140 | $2,917 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $2,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $270 | $72,71755 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $126 | $46,72243 claims |
| AstraZenecaFarxiga, Symbicort | $279 | $34,23533 claims |
| Johnson & JohnsonXarelto | $229 | $25,97632 claims |
| PfizerEliquis | $232 | $24,57617 claims |
| Lilly USA, LLCTrulicity | $34 | $21,99615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Keizer
- John DelgadoAshland$4.3M
- John MickelsonLincoln City$2.1M
- Subramaniam SeetharamanMilwaukie$1.8M
- Eden MillerBend$1.7M
- Maureen MaysPortland$491K
- Thomas TurkRoseburg$434K
- Anil RajaniHood River$325K
- Patricia BuchananEugene$239K
- Keith KlattAstoria$166K
- Stephen NelsonMedford$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.